Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications.
Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriakou C, Goldstone AH, Mackinnon S, Hale G. Morris EC, et al. Among authors: kyriakou c. Blood. 2003 Jul 1;102(1):404-6. doi: 10.1182/blood-2002-09-2687. Epub 2003 Mar 6. Blood. 2003. PMID: 12623851 Free article. Clinical Trial.
SARS-CoV-2 Infection in Patients With Waldenström's Macroglobulinemia: A Multicenter International Cohort Study.
Defrancesco I, Ferretti VV, Morel P, Kyriakou C, Kastritis E, Tohidi-Esfahani I, Tedeschi A, Buske C, García-Sanz R, Vos JMI, Peri V, Margiotta Casaluci G, Ferrari A, Piazza F, Oostvogels R, Lovato E, Montes L, Fornecker LM, Grunenberg A, Dimopoulos MA, Tam CS, D'Sa S, Leblond V, Trotman J, Passamonti F, Arcaini L, Varettoni M. Defrancesco I, et al. Among authors: kyriakou c. Hemasphere. 2023 Jun 2;7(6):e887. doi: 10.1097/HS9.0000000000000887. eCollection 2023 Jun. Hemasphere. 2023. PMID: 37283569 Free PMC article. No abstract available.
Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing.
Arulogun SO, Brian D, Goradia H, Cooney A, Menne T, Koo R, O'Neill AT, Vos JMI, Pratt G, Turner D, Marshall K, Manos K, Anderson C, Gavriatopoulou M, Kyriakou C, Kersten MJ, Minnema MC, Koutoumanou E, El-Sharkawi D, Linton K, Talaulikar D, McCarthy H, Bishton M, Follows G, Wechalekar A, D'Sa SP. Arulogun SO, et al. Among authors: kyriakou c. Am J Hematol. 2023 May;98(5):750-759. doi: 10.1002/ajh.26895. Epub 2023 Mar 20. Am J Hematol. 2023. PMID: 36866925 Free article.
The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT.
Tournilhac O, van Gelder M, Eikema DJ, Zinger N, Dreger P, Bornhäuser M, Vucinic V, Scheid C, Cornelissen JJ, Schroeder T, Jindra P, Sengeloev H, Nguyen Quoc S, Stelljes M, Blau IW, Mayer J, Paneesha S, Chevallier P, Forcade E, Kröger N, Blaise D, Gribben J, Nielsen B, Johansson JE, Kyriakou C, Beguin Y, Pioltelli P, Sampol A, McLornan DP, Schetelig J, Hayden PJ, Yakoub-Agha I. Tournilhac O, et al. Among authors: kyriakou c. Bone Marrow Transplant. 2023 Jun;58(6):621-624. doi: 10.1038/s41409-023-01955-z. Epub 2023 Mar 28. Bone Marrow Transplant. 2023. PMID: 36977926 Free PMC article. Review.
International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20).
Oerlemans S, Efficace F, Kyriakou C, Freitas AC, Shamieh O, Creutzberg CL, Lehmann J, Petranovic D, Nagele E, Bredart A, Dong D, Scholz CW, Caocci G, Molica S, Griskevicius L, Xochelli A, Kieffer JM, Agelink van Rentergem JA, Alrjoub W, Mueller A, Gomes Da Silva M, Alves da Costa F, Malak S, Cocks K, van de Poll-Franse LV; EORTC Quality of Life Group. Oerlemans S, et al. Among authors: kyriakou c. Cancer. 2023 Sep 1;129(17):2727-2740. doi: 10.1002/cncr.34822. Epub 2023 May 19. Cancer. 2023. PMID: 37204189
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS, Mackinnon S, Williams CD, D'Sa S, Thuraisundaram D, Kyriakou C, Morris EC, Hale G, Waldmann H, Linch DC, Goldstone AH, Yong K. Peggs KS, et al. Among authors: kyriakou c. Biol Blood Marrow Transplant. 2003 Apr;9(4):257-65. doi: 10.1053/bbmt.2003.50009. Biol Blood Marrow Transplant. 2003. PMID: 12720218 Free article. Clinical Trial.
111 results